AccuraGen: Advancing Cancer Management with Whole Genome Sequencing Multi-Cancer Diagnostic
AccuraGen is pioneering next-gen sequencing (NGS) technologies in genomics and bioinformatics to accurately analyze a person’s risk of developing cancer or relapsing after surgery. The company’s flagship technology platform, AccuScan, is a targeted, whole genome sequencing (WGS) multi-cancer diagnostic that analyzes a patient’s blood with a machine-learning algorithm and a proprietary bioinformatics database. AccuraGen’s rolling-circle amplification technology offers several potential competitive advantages over competitors, including accuracy, cost, timing, and scalability.
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- AccuraGen’s technology is different. The company utilizes CLAmp sequencing, or “rolling circle” amplification, where copies are only made from the original ctDNA strain found in the patient's blood. Less copies. More accuracy.
- The company's AccuScan product is more scalable and democratized than competitors, which should result in a highly attractive pitch to hospitals and labs looking to set up on-site MRD testing.
- MRD monitoring to be a $27 billion market by 2027. AccuraGen has a high performance, democratized solution to compete with Roche, Guardant, and Natera.
Click image above to view full announcement.
Contacts:
Chelli Miller
2199216823
chelli@contentcarnivores.com
Source: AccuraGen
Distributed by: Reportable, Inc.
